# Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.

> **NCT01258439** · PHASE4 · COMPLETED · sponsor: **St Vincent's Hospital, Sydney** · enrollment: 25 (actual)

## Conditions studied

- HIV
- Cardiovascular Disease

## Interventions

- **DRUG:** raltegravir plus truvada
- **DRUG:** Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)

## Key facts

- **NCT ID:** NCT01258439
- **Lead sponsor:** St Vincent's Hospital, Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258439, "Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01258439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*